DST-8294

DST-8294 is an investigational **small-molecule** drug being developed by **DisperSol Technologies** for **antiphospholipid syndrome** and related clotting disorders. Publicly available sources identify it as an early-stage pipeline asset, but they do **not** provide a clearly disclosed molecular identity, pharmacologic target, or confirmed mechanism of action. Based on available pipeline descriptions, it appears to be a proprietary oral formulation candidate within DisperSol's portfolio rather than an approved medicine, and its clinical development appears to have remained at an early phase with limited public detail.